Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 432


Single Particle Tracking Reveals that EGFR Signaling Activity Is Amplified in Clathrin-Coated Pits.

Ibach J, Radon Y, Gelléri M, Sonntag MH, Brunsveld L, Bastiaens PI, Verveer PJ.

PLoS One. 2015 Nov 17;10(11):e0143162. doi: 10.1371/journal.pone.0143162. eCollection 2015.


miR-1290 is a potential prognostic biomarker in non-small cell lung cancer.

Mo D, Gu B, Gong X, Wu L, Wang H, Jiang Y, Zhang B, Zhang M, Zhang Y, Xu J, Pan S.

J Thorac Dis. 2015 Sep;7(9):1570-9. doi: 10.3978/j.issn.2072-1439.2015.09.38.


Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway.

Son DJ, Hong JE, Ban JO, Park JH, Lee HL, Gu SM, Hwang JY, Jung MH, Lee DW, Han SB, Hong JT.

Biomed Res Int. 2015;2015:397563. doi: 10.1155/2015/397563. Epub 2015 Sep 28.


Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.

Darr J, Klochendler A, Isaac S, Geiger T, Eden A.

Mol Cancer. 2015 Sep 15;14:167. doi: 10.1186/s12943-015-0439-5.


RhNRG-1β Protects the Myocardium against Irradiation-Induced Damage via the ErbB2-ERK-SIRT1 Signaling Pathway.

Gu A, Jie Y, Sun L, Zhao S, E M, You Q.

PLoS One. 2015 Sep 2;10(9):e0137337. doi: 10.1371/journal.pone.0137337. eCollection 2015.


Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.

Lococo F, Paci M, Rapicetta C, Rossi T, Sancisi V, Braglia L, Cavuto S, Bisagni A, Bongarzone I, Noonan DM, Albini A, Maramotti S.

Int J Mol Sci. 2015 Aug 19;16(8):19612-30. doi: 10.3390/ijms160819612.


Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells.

Capuani F, Conte A, Argenzio E, Marchetti L, Priami C, Polo S, Di Fiore PP, Sigismund S, Ciliberto A.

Nat Commun. 2015 Aug 12;6:7999. doi: 10.1038/ncomms8999.


Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, Castro V, Murga-Penas EM, Collazo-Lorduy A, Castillo-Martin M, Alvarez M, Cordon-Cardo C, Kalinsky K, Maurer M, Califano A, Silva JM.

Genes Dev. 2015 Aug 1;29(15):1631-48. doi: 10.1101/gad.262642.115. Epub 2015 Jul 30.


Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers.

Kirouac DC, Lahdenranta J, Du J, Yarar D, Onsum MD, Nielsen UB, McDonagh CF.

CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00019. doi: 10.1002/psp4.19. Epub 2015 Mar 4.


Inflammation-induced desmoglein-2 ectodomain shedding compromises the mucosal barrier.

Kamekura R, Nava P, Feng M, Quiros M, Nishio H, Weber DA, Parkos CA, Nusrat A.

Mol Biol Cell. 2015 Sep 15;26(18):3165-77. doi: 10.1091/mbc.E15-03-0147. Epub 2015 Jul 29.


Intracellular sphingosine kinase 2-derived sphingosine-1-phosphate mediates epidermal growth factor-induced ezrin-radixin-moesin phosphorylation and cancer cell invasion.

Adada MM, Canals D, Jeong N, Kelkar AD, Hernandez-Corbacho M, Pulkoski-Gross MJ, Donaldson JC, Hannun YA, Obeid LM.

FASEB J. 2015 Nov;29(11):4654-69. doi: 10.1096/fj.15-274340. Epub 2015 Jul 24.


In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.

Yosef HK, Mavarani L, Maghnouj A, Hahn S, El-Mashtoly SF, Gerwert K.

Anal Bioanal Chem. 2015 Nov;407(27):8321-31. doi: 10.1007/s00216-015-8875-z. Epub 2015 Jul 14.


Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells.

Kretschmer I, Freudenberger T, Twarock S, Fischer JW.

Br J Pharmacol. 2015 Jul 3. doi: 10.1111/bph.13240. [Epub ahead of print]


Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.

Blancafort A, Giró-Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ò, Carrión-Salip D, Massaguer A, Brugada R, Palafox M, Gómez-Miragaya J, González-Suárez E, Puig T.

PLoS One. 2015 Jun 24;10(6):e0131241. doi: 10.1371/journal.pone.0131241. eCollection 2015.


The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Diver EJ, Foster R, Rueda BR, Growdon WB.

Oncologist. 2015 Sep;20(9):1058-68. doi: 10.1634/theoncologist.2015-0149. Epub 2015 Jun 22.


Sulforaphane attenuates EGFR signaling in NSCLC cells.

Chen CY, Yu ZY, Chuang YS, Huang RM, Wang TC.

J Biomed Sci. 2015 Jun 3;22:38. doi: 10.1186/s12929-015-0139-x.


Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26.


Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation.

Venè R, Tosetti F, Minghelli S, Poggi A, Ferrari N, Benelli R.

Oncotarget. 2015 May 20;6(14):12310-25.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk